Clinical Trial: Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

U.S., April 12 -- ClinicalTrials.gov registry received information related to the study (NCT06924606) titled 'Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy' on April 06.

Brief Summary: This is a single-arm, open phase II clinical trial evaluating the safety, tolerability,and preliminary efficacy of JS207 in NSCLC after progression following Platinum-based chemotherapy and immunotherapy

Study Start Date: May 15

Study Type: INTERVENTIONAL

Condition: Advanced NSCLC

Intervention: DRUG: JS207 injection

Q3W or until the patient develops PD, intolerable toxicity, death, loss of follow-up, voluntary withdrawal, or the end of the study, whichever occ...